These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat. Park SH; Farooq MA; Gaertner S; Bruckert C; Qureshi AW; Lee HH; Benrahla D; Pollet B; Stephan D; Ohlmann P; Lessinger JM; Mayoux E; Auger C; Morel O; Schini-Kerth VB Cardiovasc Diabetol; 2020 Feb; 19(1):19. PubMed ID: 32070346 [TBL] [Abstract][Full Text] [Related]
3. Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation. Kolijn D; Pabel S; Tian Y; Lódi M; Herwig M; Carrizzo A; Zhazykbayeva S; Kovács Á; Fülöp GÁ; Falcão-Pires I; Reusch PH; Linthout SV; Papp Z; van Heerebeek L; Vecchione C; Maier LS; Ciccarelli M; Tschöpe C; Mügge A; Bagi Z; Sossalla S; Hamdani N Cardiovasc Res; 2021 Jan; 117(2):495-507. PubMed ID: 32396609 [TBL] [Abstract][Full Text] [Related]
4. Empagliflozin protects against heart failure with preserved ejection fraction partly by inhibiting the senescence-associated STAT1-STING axis. Shi Y; Zhao L; Wang J; Liu X; Bai Y; Cong H; Li X Cardiovasc Diabetol; 2024 Jul; 23(1):269. PubMed ID: 39044275 [TBL] [Abstract][Full Text] [Related]
5. Empagliflozin Preserves Skeletal Muscle Function in a HFpEF Rat Model. Winzer EB; Schauer A; Langner E; Augstein A; Goto K; Männel A; Barthel P; Jannasch A; Labeit S; Mangner N; Linke A; Adams V Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232292 [TBL] [Abstract][Full Text] [Related]
11. Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics. Santos-Gallego CG; Requena-Ibanez JA; San Antonio R; Ishikawa K; Watanabe S; Picatoste B; Flores E; Garcia-Ropero A; Sanz J; Hajjar RJ; Fuster V; Badimon JJ J Am Coll Cardiol; 2019 Apr; 73(15):1931-1944. PubMed ID: 30999996 [TBL] [Abstract][Full Text] [Related]
12. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Habibi J; Aroor AR; Sowers JR; Jia G; Hayden MR; Garro M; Barron B; Mayoux E; Rector RS; Whaley-Connell A; DeMarco VG Cardiovasc Diabetol; 2017 Jan; 16(1):9. PubMed ID: 28086951 [TBL] [Abstract][Full Text] [Related]
13. Targeting MuRF1 by small molecules in a HFpEF rat model improves myocardial diastolic function and skeletal muscle contractility. Adams V; Schauer A; Augstein A; Kirchhoff V; Draskowski R; Jannasch A; Goto K; Lyall G; Männel A; Barthel P; Mangner N; Winzer EB; Linke A; Labeit S J Cachexia Sarcopenia Muscle; 2022 Jun; 13(3):1565-1581. PubMed ID: 35301823 [TBL] [Abstract][Full Text] [Related]
14. Beneficial Effect of the SGLT2 Inhibitor Empagliflozin on Glucose Homeostasis and Cardiovascular Parameters in the Cohen Rosenthal Diabetic Hypertensive (CRDH) Rat. Younis F; Leor J; Abassi Z; Landa N; Rath L; Hollander K; Naftali-Shani N; Rosenthal T J Cardiovasc Pharmacol Ther; 2018 Jul; 23(4):358-371. PubMed ID: 29627992 [TBL] [Abstract][Full Text] [Related]
15. Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction. Zhang N; Feng B; Ma X; Sun K; Xu G; Zhou Y Cardiovasc Diabetol; 2019 Aug; 18(1):107. PubMed ID: 31429767 [TBL] [Abstract][Full Text] [Related]
16. Direct Cardiac Actions of the Sodium Glucose Co-Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure-Overload Heart Failure. Li X; Lu Q; Qiu Y; do Carmo JM; Wang Z; da Silva AA; Mouton A; Omoto ACM; Hall ME; Li J; Hall JE J Am Heart Assoc; 2021 Mar; 10(6):e018298. PubMed ID: 33719499 [TBL] [Abstract][Full Text] [Related]
17. Empagliflozin Significantly Prevents the Doxorubicin-induced Acute Cardiotoxicity via Non-antioxidant Pathways. Barış VÖ; Dinçsoy AB; Gedikli E; Zırh S; Müftüoğlu S; Erdem A Cardiovasc Toxicol; 2021 Sep; 21(9):747-758. PubMed ID: 34089496 [TBL] [Abstract][Full Text] [Related]
18. Adenosine Kinase Inhibition Augments Conducted Vasodilation and Prevents Left Ventricle Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction. Davila A; Tian Y; Czikora I; Li J; Su H; Huo Y; Patel V; Robinson V; Kapuku G; Weintraub N; Bagi Z Circ Heart Fail; 2019 Aug; 12(8):e005762. PubMed ID: 31525084 [TBL] [Abstract][Full Text] [Related]